Latest news and press releases about Vertex Pharmaceuticals Incorporated (VRTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
Price
| Price | $503.50 |
| Market Cap | $127.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 29.38 |
| Price / Book | 6.21 |
| EV / EBITDA | 23.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 21.18% |
| Return on Invested Capital | 18.12% |
| Return on Assets | 15.12% |
| Gross Margin | 85.03% |
| Operating Margin | 39.43% |
| Net Margin | 32.74% |
Related companies: ARGX · BMY · CVS · GSK · HCA · MCK · MDT
Explore sector: Healthcare · Biotechnology
More sections of VRTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks